Dosimetric validation of a magnetic resonance image gated radiotherapy system using a motion phantom and radiochromic film. by Lamb, James M et al.
UCLA
UCLA Previously Published Works
Title
Dosimetric validation of a magnetic resonance image gated radiotherapy system using a 
motion phantom and radiochromic film.
Permalink
https://escholarship.org/uc/item/38z181pf
Journal
Journal of applied clinical medical physics, 18(3)
ISSN
1526-9914
Authors
Lamb, James M
Ginn, John S
O'Connell, Dylan P
et al.
Publication Date
2017-05-01
DOI
10.1002/acm2.12088
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
R AD I A T I ON ONCO LOG Y PH Y S I C S
Dosimetric validation of a magnetic resonance image gated
radiotherapy system using a motion phantom and
radiochromic film
James M. Lamb1 | John S. Ginn1 | Dylan P. O’Connell1 | Nzhde Agazaryan1 |
Minsong Cao1 | David H. Thomas2 | Yingli Yang1 | Mircea Lazea3 | Percy Lee1 |
Daniel A. Low1
1Department of Radiation Oncology, David
Geffen School of Medicine, University of
California, Los Angeles, CA, USA
2Department of Radiation Oncology,
University of Colorado Denver, Denver,
CO, USA
3Computerized Imaging Reference Systems,
Inc., Norfolk, VA, USA
Author to whom correspondence should be
addressed. James M. Lamb
E-mail: JLamb@mednet.ucla.edu.
Abstract
Purpose: Magnetic resonance image (MRI) guided radiotherapy enables gating
directly on the target position. We present an evaluation of an MRI-guided radio-
therapy system’s gating performance using an MRI-compatible respiratory motion
phantom and radiochromic film. Our evaluation is geared toward validation of our
institution’s clinical gating protocol which involves planning to a target volume
formed by expanding 5 mm about the gross tumor volume (GTV) and gating based
on a 3 mm window about the GTV.
Methods: The motion phantom consisted of a target rod containing high-contrast tar-
get inserts which moved in the superior-inferior direction inside a body structure con-
taining background contrast material. The target rod was equipped with a
radiochromic film insert. Treatment plans were generated for a 3 cm diameter spheri-
cal planning target volume, and delivered to the phantom at rest and in motion with
and without gating. Both sinusoidal trajectories and tumor trajectories measured dur-
ing MRI-guided treatments were used. Similarity of the gated dose distribution to the
planned, motion-frozen, distribution was quantified using the gamma technique.
Results: Without gating, gamma pass rates using 4%/3 mm criteria were 22–59%
depending on motion trajectory. Using our clinical standard of repeated breath holds
and a gating window of 3 mm with 10% target allowed outside the gating boundary,
the gamma pass rate was 97.8% with 3%/3 mm gamma criteria. Using a 3 mm win-
dow and 10% allowed excursion, all of the patient tumor motion trajectories at
actual speed resulting in at least 95% gamma pass rate at 4%/3 mm.
Conclusions: Our results suggest that the device can be used to compensate respiratory
motion using a 3 mm gating margin and 10% allowed excursion results in conjunction
with repeated breath holds. Full clinical validation requires a comprehensive evaluation
of tracking performance in actual patient images, outside the scope of this study.
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1 | INTRODUCTION
Radiation therapy provides an effective way to combat numerous
types of cancer, improving both a patient’s quality and quantity of
life. However, the effectiveness of a radiation treatment is limited by
the accuracy and precision of the treatment’s delivery. One of the
greatest challenges limiting the accurate and precise delivery of a
treatment plan is patient motion arising from respiratory, cardiac and
gastrointestinal peristaltic processes. Numerous respiratory motion
management techniques have been developed1, such as tumor track-
ing, 4D-CT based internal target volumes, and respiratory gating.
Extensive clinical experience exists for respiratory gating performed
using external surrogates2–4 and implanted fiducial markers5–7. Surro-
gate-based tracking suffers from the fact that the relationship
between the surrogate and the tumor position may vary in time8–10.
Implanted fiducials are associated with a small but non-negligible risk
of injury, cannot be easily implanted in all anatomic locations subject
to respiratory motion, may change position in the body over time,
and cannot easily capture target deformation11–14. Magnetic reso-
nance image (MRI) guided radiotherapy enables gating directly on
target position for soft-tissue targets in the lung and abdomen with-
out implanted markers15. Currently, the only FDA-approved MRI-
guided radiotherapy system is the ViewRay MRIdian (ViewRay, Inc.,
Cleveland, OH, USA). In this paper, we present a dosimetric evalua-
tion of the MRIdian’s respiratory gating performance using an MRI-
compatible motion phantom and radiochromic film. Our methodology
is to perform static, gated moving, and ungated moving deliveries of
the same plan and evaluate the gating performance in terms of its
ability to “freeze” motion, i.e., quantitate the difference between
each case and the static treatment plan using the gamma16 metric.
This methodology has been frequently used to evaluate gating sys-
tems17–23. The purpose of this study was to establish a technical
performance baseline of the respiratory gating which can inform clin-
ical gating protocols as well as be used as a machine performance
benchmark by other institutions.
The MRIdian can gate treatments based on planar images
acquired during treatment. The gating is based on tumor tracking by
deformable image registration. Real-time images can be acquired in a
single sagittal plane at 4 Hz or in three sagittal planes at 2 Hz.
Because the additional 0.25 s of beam-off latency required when
using three-plane imaging, our institutional policy is to not use
three-plane imaging, and it was not evaluated in this study. Our
institution’s clinical gating protocol uses the MRIdian’s gating capa-
bilities as follows. The gating target is contoured on the volumetric
scan used for treatment planning. The gating target is usually the
gross tumor volume (GTV), but could be a critical organ at risk or a
surrogate structure. For best performance, the gating target contour
should correspond to a strong contrast boundary in the image. For
every treatment fraction, the target contour is transferred either
rigidly or deformably to a volumetric pretreatment setup image. The
target contour is optionally updated manually. Both the setup image
and the simulation image are acquired under voluntary breath hold
of 17 or 25 s duration depending on the imaging field of view. Sub-
sequently, a two-dimensional cine preview scan is acquired with a
frame rate of four frames per second in a single sagittal plan cen-
tered on the tumor. The cine preview scan is acquired under free
breathing conditions. Each frame of the preview scan is deformably
registered to the volumetric setup image by the MRIdian software.
Contours are propagated from the setup image to the best-matching
cine frame, called the key frame. During treatment, the now two-
dimensional gating target contour is propagated from the key frame
to each cine image in real time. If the propagated target contour
exceeds a preset boundary by a configurable percentage of its area,
the treatment beam is held. The boundary corresponds either to a
numerical expansion relative to the gating target’s initial location, or
to another contour from the planning volumetric image (e.g., the
planning target volume).
Our clinical protocol uses repeated breath holds throughout the
treatment duration. The MRIdian system tracks the target and
enables beam only when the target is within a predefined boundary;
repeated breath holds are used to maximize the duty cycle and mini-
mize dosimetric error due to beam hold latency. A margin of 3 mm
around the gross tumor volume (GTV) position in the volumetric
setup scan is used as the gating boundary, and a 10% excursion of
the tracked GTV contour outside the boundary is allowed. The 10%
allowed excursion is used to make the gating procedure robust to
random errors in contour tracking arising from image noise.
Repeated breath holds are used by preference if the patient is
able to perform them at consistent states of inhalation, with coach-
ing if needed. If the patient is not able to perform consistent
repeated breath holds, free breathing is used at the discretion of the
attending physician. If the gating efficiency is sufficiently low that
the patient may not be able to tolerate the treatment time, the gat-
ing margin may be relaxed from 3 mm to 5 mm at the discretion of
the attending physician.
2 | MATERIALS AND METHODS
2.A | Motion phantom
Respiratory motion was simulated using a MRI-compatible phantom
that was capable of one-dimensional motion in the superior-inferior
direction (Fig. 1). The phantom was developed by CIRS, Inc (Norfolk,
VA, USA), with input from ViewRay and is commercially available
from CIRS. The phantom consists of a stationary body structure
filled with background contrast material and four small spheres of
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high-contrast material. A 6.5 cm diameter target rod was made to
move within the body structure by a stepper motor. The target rod
included three regions of high-contrast material (a small sphere, a
small cuboid, and a large cylinder) within and adjacent to a back-
ground contrast region. In standard configuration, the target rod
includes an ion chamber insert. A custom target rod with a film
insert was developed by CIRS to our specification. A cross-section
of the target rod is shown in Fig. 2. The entire body structure,
excluding a 1 cm acrylic supporting shell, is approximately water
equivalent.
2.B | Treatment planning
A treatment plan was produced using the ViewRay treatment planning
system and delivered on the MRIdian system. The planning target vol-
ume (PTV) was a 3 cm diameter sphere. The plan contained 15 copla-
nar beams and the dose distribution was typical for a stereotactic
body radiotherapy plan, scaled to a maximum dose 3.75 Gy per frac-
tion to lie within the dynamic range of EBT3 film. In addition, a
2.1 cm 9 1.05 cm reference beam delivering 2.4 Gy per fraction at
the film surface was added at a 6.5 cm longitudinal isocenter shift rela-
tive to the PTV isocenter. The reference beam was used for film spatial
registration and dose calibration as described below. Figure 2a shows
the dose distribution at the surface of the film.
2.C | Radiochromic film dosimetry
Gafchromic EBT3 radiochromic film (Ashland, Inc, Bridgewater, NJ,
USA) was loaded in the phantom and carefully aligned to a raised
fiducial reference line in the insert. To minimize the uncertainty in
alignment due to cutting the film, the side of the film that was not
cut was aligned to this reference line. FilmQA Pro 2015 (Ashland,
Inc, Bridgewater, NJ, USA) with the triple-channel algorithm24 was
used for all film analysis. Calibration films from the same lot of film
used for experiments were exposed at nine dose levels between 0
and 500 cGy using the MRIdian machine. Film was read using an
Epson 10000 XL scanner (Epson America, Inc., Long Beach, CA,
USA) at least 24 hr after irradiation. Delivered dose distributions
were compared to the planned dose distributions using the gamma
technique16, with 3 mm distance to agreement and 3%, 4%, and 5%
global dose difference tolerance, and regions with dose less than
30% of the maximum dose were suppressed.
A 2.1 cm 9 1.05 cm reference beam at a distance of 6.5 cm
from the PTV isocenter was delivered with the phantom at rest after
F I G . 1 . Side view of the CIRS MRI-
compatible motion phantom.
F I G . 2 . Target rod cross-section MRI
image with isodose distribution
superimposed (a) and optical digital camera
image (b). The reference beam appears on
the left and the PTV on the right in this
view. The PTV is a 3 cm diameter spherical
target centered about the cuboid gating
target.
F I G . 3 . Patient tumor motion trajectories used in this study,
including repeated breath hold (a) and free breathing (b) and (c).
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every motion trajectory. The reference beam was used to spatially
register the film to the treatment plan in the software used for film
dosimetry FilmQA. The reference beam was also used to extract a
relative dose scaling factor to account for inter-scan differences in
film calibration. The spatial registration and the dose scaling factor
were derived by iterative maximization of the gamma passing rate in
an ROI including only the reference beam.
2.D | Breathing waveforms
An artificial breathing waveform at two frequencies and three
actual tumor trajectories were used for phantom motion. The artifi-
cial breathing wave was a cos6 function, which was used to repre-
sent an idealized human breathing pattern which was asymmetric
with more time spent at exhalation than inhalation. Trajectory
amplitude was 2 cm peak-to-peak and both 10 and 15 breaths per
minute frequencies were used. The actual tumor trajectories were
derived from real-time MRI imaging acquired at four frames per
second during abdominal radiotherapy treatments on the MRIdian
machine, and are shown in Fig. 3. One trajectory was acquired dur-
ing repeated voluntary breath hold at exhalation, and the other
two were acquired during free breathing. To test the robustness of
gating to rapid breathing, sped-up versions of each trajectory were
also tested. Trajectory properties are listed in Table 1. Trajectories
were looped throughout the duration of treatment delivery.
3 | RESULTS
For the static delivery, 96.5% of points passed the gamma criteria at
3%/3 mm tolerance. Dosimetric accuracy relative to the static treat-
ment plan under different motion trajectories and with different gat-
ing parameters is shown in Table 2. Using 3 mm gating window and
10% allowed excursion, the breath hold trajectory at actual speed
had 97.8% gamma pass rate at 3%/3 mm criteria, and all of the
patient tumor motion trajectories at actual speed had at least 95%
gamma pass rate at 4%/3 mm. Dosimetric accuracy for the artificially
sped-up trajectories is shown in Table 3. Accuracy was noticeably
less for the artificially sped-up trajectories and for the sinusoidal tra-
jectories. Considering all trajectories, increased accuracy is observed
for 3 mm versus 5 mm gating margin (P < 0.004) and for 5% allowed
excursion versus 10% allowed excursion (P = 0.005). Statistical test-
ing was performed with three-way ANOVA using margin size,
allowed excursion, and breathing trajectory as grouping variables.
TAB L E 1 Characteristics of breathing waves.
N Description
Amplitude
(5th–95th) Duration Mean period
1 Repeated Breath hold 19 mm 210 s NA
2 Free breathing 1 21 mm 45 s 3.2 s/breath
3 Free breathing 2 19 mm 111 s 4.0 s/breath
4* Fast Repeated breath hold 19 mm 105 s NA
5* Fast free breathing 1 21 mm 23 s 1.6 s/breath
6* Fast free breathing 2 19 mm 28 s 1.0 s/breath
*Trajectories 4, 5, and 6 are copies of trajectories 1, 2, and 3 sped up by
factors of 2, 2, and 4, respectively.
TAB L E 2 The individual exposure results of gating experiments with patient tumor motion trajectories and sinusoidal trajectories.
Trajectory Gating parameters Duty cycle Gamma 3%, 3 mm Gamma 4%, 3 mm Gamma 5%, 3 mm
Breath hold None 100% 49.9% 59.4% 66.9%
Breath hold 3 mm, 5% 78.3% 95.2% 98.8% 100%
Breath hold 3 mm, 10% 81.5% 97.8% 99.2% 100%
Breath hold 5 mm, 10% 80.6% 89.5% 96.5% 99.8%
Free breathing 1 None 100% 25.0% 27.7% 30.6%
Free breathing 1 3 mm, 5% 56.7% 91.7% 98.2% 100%
Free breathing 1 3 mm, 10% 61.9% 91.6% 98.2% 100%
Free breathing 1 5 mm, 10% 66.0% 81.0% 90.5% 93.8%
Free breathing 2 None 100% 32.9% 37.2% 41.9%
Free breathing 2 3 mm, 5% 56.9% 98.6% 100% 100%
Free breathing 2 3 mm, 10% 74.8% 89.5% 97.1% 99.8%
Free breathing 2 5 mm, 10% 71.5% 88.7% 95.8% 99.6%
Cos6 10 bpm None 100% 24.1% 26.3% 28.9%
Cos6 10 bpm 3 mm, 5% 61% 87.13 95.45% 99.21%
Cos6 10 bpm 3 mm, 10% 75% 76.6% 86.3% 94.15%
Cos6 10 bpm 5 mm, 10% 72.9% 69.7% 79.19% 84.68%
Cos6 15 bpm None 100% 26.95 30.86 34.2%
Cos6 15 bpm 3 mm, 5% 70% 64.85% 74.62% 84.96%
Cos6 15 bmp 3 mm, 10% 68.8% 53.15% 60.99% 68.8%
Cos6 15 bpm 5 mm, 10% 75.8% 42.04% 94.9% 57.96%
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The dose profile tool in FilmQA Pro was used to better under-
stand how the gating affects the dose distribution in the inferior-
superior direction. Figure 4 shows the measured gated and nongated
dose profiles as well as the planned dose profile in the direction of
motion and through the center of the reference beam and the PTV.
The motion profile used for this figure was a cos6 function with a
period of 6 s and 2 cm amplitude. The gated exposure used a 3 mm
gating margin with a 10% allowed excursion. Contrary to our initial
expectation, a shift of the profile in the direction of motion appears
more pronounced than the broadening of the dose profile. The
recovery of the static distribution by gating using a 3 mm margin is
well visualized.
4 | DISCUSSION
The gamma pass rate for our preferred clinical gating protocol (re-
peated breath holds, 3 mm gating margin, 10% excursion tolerance)
was as good as the gamma pass rate of a static delivery using 3%/
3 mm criteria, indicating that under such a protocol, phantom motion
is completely compensated. For both free-breathing measured tumor
trajectories, 3 mm gating margin and 10% excursion tolerance
resulted in pass rates above 95% for 4%/3 mm criteria. Our standard
MRI-gated protocol uses a 5 mm PTV margin, so a residual 2 mm of
margin is available to account for motion-unrelated uncertainty.
Increasing the gating margin to 5 mm resulted in a statistically signif-
icantly reduction in accuracy, however, accuracy was still adequate
in most cases, compared to an overall target dose uncertainty goal
of 5%.
In the case of free breathing tumor trajectories that were artifi-
cially sped up to 1.0 and 1.6 s per breath, as well as the cos6 trajec-
tories, dosimetric accuracy was reduced. Lowering the allowed
excursion from 10 to 5% recovered the accuracy somewhat. It is
important to note that this does not necessarily mean that a tumor
moving in such a trajectory would be under-dosed. Determining ade-
quacy of coverage requires a comprehensive assessment of a
complex set of uncertainties as well as consideration of the PTV
margin, which is beyond the scope of this paper. Quantitative
assessment of the dose accumulated to the CTV given a PTV margin
is hampered by the fact that PTV margins are designed to compen-
sate for multiple uncertainties in planning, setup and delivery, not
just motion, as well as the lack of three-dimensional information pro-
vided by a film measurement. Our result support the use of a PTV
margin for patients treated with breath hold gating that is similar to
those treated to static targets not subject to respiratory motion.
Conversely, our results indicate that care should be taken in the case
of very rapid breathers. A breathing rate of one breath per second
would certainly be unusual, but not inconceivable. A limitation of
TAB L E 3 The individual exposure results of gating experiments with artificially sped up measured tumor trajectories.
Trajectory Gating parameters Duty cycle Gamma 3%, 3 mm Gamma 4%, 3 mm Gamma 5%, 3 mm
Fast breath hold None 100% 35.80% 41.45% 47.00%
Fast breath hold 3 mm, 5% 79% 94.4% 98.6% 99.8%
Fast breath hold 3 mm, 10% 87% 91.90% 97.60% 99.60%
Fast breath hold 5 mm, 10% 81% 88.30% 94.60% 98.60%
Fast free breathing 1 None 100% 19.40% 22.20% 24.20%
Fast free breathing 1 3 mm, 5% 54% 65.50% 75.95% 83.95%
Fast free breathing 1 3 mm, 10% 61% 49.50% 56.10% 63.50%
Fast free breathing 1 5 mm, 10% 70% 43.70% 50.50% 56.50%
Fast free breathing 2 None 100% 22.60% 26.40% 29.30%
Fast free breathing 2 3 mm, 5% 55.6% 88.85% 97.30% 99.20%
Fast free breathing 2 3 mm, 10% 60% 82.15% 91.50% 95.90%
Fast free breathing 2 5 mm, 10% 63% 71.80% 82.07% 88.03%
F I G . 4 . Measured gated and non-gated, and static plan dose
profiles on a line drawn through the center of the target volume.
The small distribution on the left is the reference beam, and the
larger distribution on the right is the PTV dose profile. The dose
distribution broadens and shifts in the direction of motion when no
gating is performed. The beam profile full widths at half maximum
are 45 mm, 45 mm and 46 mm, respectively, for the planned, gated,
and ungated dose profiles, respectively. The beam profile centers are
98 mm, 99 mm, and 104 mm, respectively for the three profiles.
LAMB ET AL. | 167
our results is that the features of the phantom are idealized, and the
contrast higher than that is observed in many patients, both of
which may affect the accuracy of the tracking algorithm. A 30%
threshold was used in the gamma pass rate computation because it
is the clinical standard at our institution. To test the sensitivity of
the results to the threshold value, the comparison was repeated with
a 10% threshold for the four irradiations using the breath hold tra-
jectory, yielding a gamma pass rate lower by 0.1–2.7% (mean:1.1%).
Inaccuracies in gating result from differences in gating surrogate
versus true tumor position8,25 and latency of beam on and beam off
relative to gating signal. Real-time MRI guidance allows gating on
the actual tumor, effectively removing the first of these sources of
uncertainty. The gating latency specification of the MRIdian system
is a maximum beam-off latency of 0.5 s including the effects of 4
frames/s imaging frequency, processing time, and source shuttle
motion. Beam-off latency on our system was measured to be
0.436 s (average of 33 measurements per head). Predictive filtering
is not used by the MRIdian system. Other gating systems’ beam-off
latencies have been reported in the range of 0.044–0.529 s26–29. For
systems using predictive filtering, latency depends on breathing26.
The dosimetric error resulting from gating latency can be controlled
by minimizing the number of transitions between gated and un-
gated states, as in repeated breath hold gating. Our present study is
limited in the number of tumor trajectories studied, and further work
is needed to draw statistically significant conclusions regarding the
sensitivity of dosimetric accuracy to the amplitude, rate, and wave-
form of patient breathing. The observations of decreased accuracy
when using a 5 mm versus a 3 mm gating window, and increased
accuracy when using a 5% versus a 10% allowed excursion were
both statistically significant.
5 | CONCLUSION
This study demonstrates a baseline performance of MRI-guided gat-
ing with the ViewRay MRIdian and suggests that the device can be
used to compensate respiratory motion using a 3 mm gating margin
and 10% allowed excursion results in conjunction with repeated
breath holds. The results of this study could be used by other insti-
tutions to inform clinical gating protocols and to benchmark machine
performance. Clinical gating performance will depend on the accu-
racy of tracking in patients, which may not be as high as with the
motion phantom used for this study. A detailed investigation of
tracking performance in actual patients is warranted, but outside of
the scope of this study. A characterization of accuracy under a com-
prehensive set of breathing waveforms would also be beneficial,
because dosimetric accuracy under MRI gating depends on the
amplitude and frequency of breathing-induced motion.
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